Evidence map›Paper›PMID 41051594›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2025

A novel β-carboline alkaloid derivative targeting MDM2-p53 pathway suppresses colorectal cancer progression.

Fanbin Zeng, Cheng Chen, Zhanwei Fu, Haihui Huang, Wenqiang Cui, Yuanyuan Zhou, Yanjie Kong, Xia Liu, Zhiru Xu, Shouguo Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Discovery of Benzophenanthridine Alkaloids fromPharmaceuticals (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fanbin Zeng *School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
Cheng Chen *Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology, Shenzhen, Guangdong, 518107, China.
Zhanwei FuInstitute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Haihui HuangPathology Department, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, No. 3002 Shungang West Road, Shenzhen, 518035, China.
Wenqiang CuiInstitute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Yuanyuan ZhouFaculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology, Shenzhen, Guangdong, 518107, China.
Yanjie KongPathology Department, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, No. 3002 Shungang West Road, Shenzhen, 518035, China.
Xia LiuPathology Department, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, No. 3002 Shungang West Road, Shenzhen, 518035, China.
Zhiru XuNational Key Laboratory of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, 200437, China.
Shouguo WangInstitute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China. shouguo.wang@szu.edu.cn.
Tian XiaoSchool of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China. txiao@szu.edu.cn.
Houjun XiaFaculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology, Shenzhen, Guangdong, 518107, China. xiahoujun@suat-sz.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeColorectal cancer (CRC) remains a major global health challenge, necessitating novel therapeutic approaches. β-carboline alkaloids, natural compounds with anticancer properties, have shown potential to inhibit cancer cell viability. Here, we synthesized β-carboline derivatives and explored their potential as CRC inhibitors.

methodsThe IC

resultsZ-7 was identified as the leading candidate due to its ability to induce apoptosis and cell cycle arrest in CRC cells. Transcriptomic and proteomic data revealed that Z-7 activated the p53 signaling pathway in p53 wild-type CRC by binding to MDM2 at the RING domain, and inhibiting the E3 ligase activity of MDM2, leading to the reduction of p53 ubiquitination. In vivo study showed Z-7 treatment elevated p53 expression and significantly suppressed tumor growth in xenograft models.

conclusionZ-7 is a promising candidate for CRC therapy, particularly in patients with functional p53 and elevated MDM2, warranting further clinical evaluation.

Indexed as

AlkaloidsCarbolinesColorectal NeoplasmsDisease ProgressionProto-Oncogene Proteins c-mdm2Signal TransductionTumor Suppressor Protein p53AnimalsApoptosisCell Cycle CheckpointsCell Line, TumorCell ProliferationCell SurvivalHumansMiceMice, Inbred BALB CAlkaloidsCarbolinesMDM2 protein, humanProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53Colorectal cancerMDM2-p53 pathwaySmall-molecule compoundsβ-carboline alkaloid

Identifiers

PMID41051594
PMCPMC12698734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.